News - Fycompa, Regulation


Current filters:


Popular Filters

Eisai launches legal action after "unreasonable" delay for its epilepsy drug


Japanese drug major Eisai (TYO: 4523) has taken legal action in the USA over the delay of the recommendation…

EisaiFycompaNeurologicalNorth AmericaPharmaceuticalRegulation

Eisai gains Swiss approval for Zonegran and Canadian OK for Fycompa


Japanese drug major Eisai (TYO: 4205) says that Zonegran (zonisamide) has been approved by Switzerland's…

EisaiEuropeFycompaNeurologicalNorth AmericaPharmaceuticalRegulationZonegran

Eisai temporarily suspend Fycompa in Germany, following negative G-BA decision


Japanese drug major Eisai (TYO: 4523) said today (June 25) that, "with regret," it will suspend temporarily…

EisaiEuropeFycompaMarkets & MarketingNeurologicalPharmaceuticalPricingRegulation

Eisai slams German decision on Fycompa; Takeda files vedolizumab with EMA


The German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system…

EisaiEuropeFycompaGastro-intestinalsNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Eisai expands in South Africa, filing for approval of Halaven and Fycompa


Japanese drug major Eisai (TYO: 4523) says it is expanding its operations into South Africa, with the…

EisaiFycompaHalavenMarkets & MarketingNeurologicalOncologyPharmaceuticalRegulationRest of the World

Eisai disagrees with Germany's IQWiG report on epilepsy drug Fycompa


In the assessment report by the German Institute for Quality and Efficiency in Health Care (IQWiG) on…


Scottish Medicines Consortium approves Eisai's Fycompa and Novartis' Lucentis for DME


Japanese drug major Eisai's (TYO: 4523) Fycompa (perampanel), a treatment for partial epilepsy, is now…


FDA approves Eisai's Fycompa to treat epileptic seizures and Supernus' Oxtellar XR


The US Food and Drug Administration yesterday approved Japanese drug major Eisai's (TYO: 4523) Fycompa…

EisaiFycompaNeurologicalNorth AmericaOxtellar XRPharmaceuticalRegulationSupernus Pharmaceuticals

EU approval for Eisai's epilepsy drug Fycompa and Vertex' Kalydeco


Japanese drug major Eisai (TYO: 4523) says that the European Commission has approved for marketing its…

EisaiEuropeFycompaKalydecoNeurologicalPharmaceuticalRare diseasesRegulationVertex

Zonegran Russian approval prompts Eisai's expansion in that market


Eisai (TYO: 4523), a leading Japanese drugmaker, says it plans to expand its operations into Russia,…

EisaiEuropeFycompaHalavenMarkets & MarketingNeurologicalPharmaceuticalRegulationZonegran

Back to top